Physician profile
Michael P Wolbert
NPI 1881711778
$111,147.24
in general payments reported to CMS, 2019-2025
35 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,717 · 2020: $4,668 · 2021: $6,137 · 2022: $30K · 2023: $13K · 2024: $27K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $7,963 · Travel and Lodging: $4,252 · Education: $228 · Consulting Fee: $26.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,595.00 |
| Food and Beverage | $7,962.85 |
| Travel and Lodging | $4,252.29 |
| Education | $227.92 |
| Consulting Fee | $26.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $53,649.79 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $33,189.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,553.63 | 2019-2020 | |
| Pfizer INC. | $4,915.29 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $3,610.78 | 2025 | Neffy |
| Csl Behring | $1,798.48 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $1,322.49 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,086.34 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Grifols USA, LLC | $626.26 | 2020-2025 | Xembify |
| Mylan Specialty L.P. | $568.41 | 2019-2024 | Yupelri |
| Genzyme Corporation | $490.95 | 2019-2025 | |
| Leo Pharma INC. | $435.37 | 2022-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $334.56 | 2019-2025 | |
| Pharming Healthcare, INC. | $304.22 | 2023-2025 | Ruconest |
| Blueprint Medicines Corporation | $281.09 | 2023-2025 | Ayvakit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $273.92 | 2020-2025 | Xolair |
| Biocryst US Sales Co., LLC | $233.09 | 2021-2025 | Orladeyo |
| Amgen INC. | $198.26 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $169.72 | 2020-2021 | |
| Stryker Corporation | $151.63 | 2020 | |
| Shire North American Group INC | $120.59 | 2019 | |
| Kaleo, INC. | $113.04 | 2019-2023 | Auvi-Q |
| Organon LLC | $109.68 | 2025 | Vtama |
| Verona Pharma, INC. | $106.64 | 2025 | Ohtuvayre |
| Philips North America LLC | $95.45 | 2019-2023 | |
| Regeneron Pharmaceuticals, INC. | $87.10 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $66.91 | 2021 | |
| Lilly USA, LLC | $54.32 | 2024-2025 | Ebglyss |
| Incyte Corporation | $50.90 | 2022-2023 | Opzelura |
| Sunovion Pharmaceuticals INC. | $34.07 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $29.64 | 2025 | Dawnzera |
| Abbvie INC. | $27.15 | 2022 | |
| Adma Biomanufacturing LLC | $26.51 | 2025 | |
| Optinose US, INC. | $18.59 | 2021 | |
| Merck Sharp & Dohme LLC | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wolbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.